We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
-12.87%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$266M
AUM Growth
-$36M
(-12%)
Cap. Flow
+$40.4M
Cap. Flow
% of AUM
15.18%
Top 10 Holdings %
Top 10 Hldgs %
54.75%
Holding
84
New
18
Increased
15
Reduced
8
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Organon & Co
OGN
|
+$20.1M |
| 2 |
Cencora
COR
|
+$15.3M |
| 3 |
BCYC
Bicycle Therapeutics
BCYC
|
+$13.4M |
| 4 |
HCA Healthcare
HCA
|
+$13.3M |
| 5 |
Medtronic
MDT
|
+$8.11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$16M |
| 2 |
Sanofi
SNY
|
+$15.4M |
| 3 |
Labcorp
LH
|
+$13M |
| 4 |
McKesson
MCK
|
+$10.6M |
| 5 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$9.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.9% |
| 2 | Financials | 8.53% |
| 3 | Miscellaneous | 5.63% |
| 4 | Consumer Staples | 1.75% |
| 5 | Industrials | 0.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cencora
COR
$61.5B
| $25.9M | 9.74% |
183,334
+100,063
| +120% | +$15.3M |
|
|
MSAC
2
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
| $22.7M | 8.53% |
2,323,000
| – | – |
|
|
3
Organon & Co
OGN
$3.61B
| $19.4M | 7.29% |
+574,855
| New | +$20.1M |
|
4
Cigna
CI
$73.7B
| $14M | 5.25% |
53,034
-14,796
| -22% | -$3.81M |
|
5
Inogen
INGN
$146M
| $12.7M | 4.77% |
525,438
+125,352
| +31% | +$3.33M |
|
|
BCYC
6
Bicycle Therapeutics
BCYC
$294M
| $11.6M | 4.34% |
688,989
+636,201
| +1,205% | +$13.4M |
|
7
Centene
CNC
$32B
| $10.9M | 4.1% |
129,011
+32,249
| +33% | +$2.68M |
|
|
8
HCA Healthcare
HCA
$90.5B
| $10.4M | 3.91% |
+61,953
| New | +$13.3M |
|
9
United Therapeutics
UTHR
$22.1B
| $9.42M | 3.54% |
39,959
-15,303
| -28% | -$3.11M |
|
10
PUT
Bausch Health
BHC
$2.36B
| $8.72M | 3.27% |
1,042,700
+1,030,600
| +8,517% | +$14.4M |
|
|
NARI
11
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $7.65M | 2.87% |
112,466
+72,256
| +180% | +$5.19M |
|
12
Biogen
BIIB
$32.3B
| $7.32M | 2.75% |
+35,900
| New | +$7.34M |
|
|
13
Medtronic
MDT
$117B
| $7.18M | 2.7% |
+80,000
| New | +$8.11M |
|
14
Sight Sciences
SGHT
$471M
| $6.52M | 2.45% |
+724,944
| New | +$6.38M |
|
|
NTUS
15
DELISTED
Natus Medical Inc
NTUS
| $6.26M | 2.35% |
190,956
-608
| -0.3% | -$19.2K |
|
16
Cardinal Health
CAH
$54.6B
| $6.22M | 2.34% |
+119,061
| New | +$6.77M |
|
17
Tenet Healthcare
THC
$21.5B
| $5.52M | 2.07% |
+105,000
| New | +$7.31M |
|
18
Vanda Pharmaceuticals
VNDA
$320M
| $5.33M | 2% |
488,965
+326,487
| +201% | +$3.38M |
|
|
BHVN
19
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $5.1M | 1.92% |
+35,000
| New | +$4.47M |
|
20
SkinHealth Systems
SKIN
$89.1M
| $4.66M | 1.75% |
+362,294
| New | +$4.85M |
|
|
INBX
21
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $4.14M | 1.56% |
365,210
+240,960
| +194% | +$3.54M |
|
22
Universal Health Services
UHS
$10.1B
| $4.1M | 1.54% |
+40,725
| New | +$5.1M |
|
|
HSKA
23
DELISTED
Heska Corp
HSKA
| $3.74M | 1.4% |
+39,566
| New | +$4.27M |
|
|
PNT
24
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $3.44M | 1.29% |
504,545
+126,861
| +34% | +$971K |
|
|
HZNP
25
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $3.19M | 1.2% |
+40,000
| New | +$3.79M |
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, Sio Capital Management held 84 positions worth $266M, down 12% from $302M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Sio Capital Management deployed $40.4M of net new capital in Q2 2022, opening 18 new positions and adding to 15 existing holdings. Its largest new stake was Organon & Co: 574,855 shares worth $19.4M.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 73% a quarter earlier, followed by Financials and Miscellaneous.
On the sell side, the largest reduction was Cigna, an estimated $3.81M trimmed.
- Sio Capital Management's largest Q2 2022 buy was Organon & Co: 574,855 shares worth $19.4M.
- Sio Capital Management added most to Cencora in Q2 2022, an estimated $15.3M increase.
- Sio Capital Management's biggest Q2 2022 reduction was Cigna, cutting an estimated $3.81M.
- Sio Capital Management fully exited Merck in Q2 2022, selling an estimated $16M.
- Sio Capital Management's ten largest holdings make up 55% of its $266M portfolio in Q2 2022.
- Sio Capital Management opened 18 new positions and closed 22 in Q2 2022.
- Sio Capital Management's portfolio value fell 12% quarter-over-quarter to $266M.
Based on Sio Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.